Inamed promises higher EPS (earnings per share) despite lower sales:
This article was originally published in Clinica
Inamed, a manufacturer of products for the plastic and reconstructive surgery, and obesity markets, says its sales will be lower than its mid-quarter sales update. However, second-quarter earnings per share will be at the higher end of analyst expectations, the Santa Barbara, California company says. Inamed has achieved higher earnings because it had been able to control costs. Sales were down because of the strong dollar, weaker economies in Japan and Europe, and continued weakness in the US economy.
You may also be interested in...
With many non-CE marked products being allowed onto various EU member state markets, who is going to monitor compliance? TÜV-SÜD’s Bassil Akra calls for cooperation to avoid unsafe products being used on patients.
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.